Summary: Cardiac and pulmonary diseases are still leading human killers and the coexistence of these diseases worsens the prognosis. Long-acting β-agonists (LABA) and their main representative salmeterol, are the basic option in the treatment of pulmonary disorders, but they are in disrepute from a cardiologistʼs point of view. β2-agonists may increase heart rate, worsen cardiac function, and might reduce potassium levels, thus facilitating hypokalemia-induced arrhythmias and tachycardias. But the question is whether the problem of cardiac toxicity of LABA is not exaggerated. The aim of this analysis is to answer this question.